Columbus, OH
Founders and CEO
Michael Triplett, Ph.D. Co-founder & CEO
Dr. Lauren Bakaletz, Inventor
Dr. Steven Goodman, Inventor
Life Sciences

Company Profile

Clarametyx Biosciences is a preclinical biotechnology company developing a novel, non-antibiotic therapeutic and vaccine platform to treat and prevent bacterial biofilm-mediated disease, beginning with moderate-to-severe pneumonia. Clarametyx’s paradigm shifting therapeutic approach augments the innate immune system and all antibiotic classes to clear bacterial biofilms. Clarametyx’s pioneering, patent protected technology, invented by Drs. Lauren Bakaletz and Steven Goodman, both acclaimed academic thought leaders at Nationwide Children’s Hospital and The Ohio State University, holds promise for addressing biofilm mediated infections and other diseases.

Clarametyx Biosciences in the News

Nationwide Children’s infection-busting treatment gets pivotal tests
Clarametyx Biosciences Announces $33M Series A Financing to Advance Anti-Biofilm Biologics for Serious Bacterial Infections
Clarametyx Announces Positive Early Phase 1 Safety Findings on CMTX-101, Immune-Enabling Antibody Therapy
Startups to Watch: These Central Ohio Companies Could Take Off in 2023
Otitis Media Market Size 2022 – Industry Share, Global Sales, Growth Rate with top companies – Blue Water Vaccines Inc, Ceolia Pharma Co Ltd, Clarametyx Biosciences Inc, Earnano LLC